Zobrazit v EDS

Serum, urinary and fecal concentrations of perfluoroalkyl substances after interventions with cholestyramine/colesevelam and probenecid - cross-over trials in Ronneby, Sweden

Uloženo v:
Podrobná bibliografie
Název: Serum, urinary and fecal concentrations of perfluoroalkyl substances after interventions with cholestyramine/colesevelam and probenecid - cross-over trials in Ronneby, Sweden
Autoři: Andersson, Axel G, Xu, Yiyi, Kärrman, Anna, Cederlund, Julia, Lindh, Christian H, Pineda, Daniela, Fletcher, Tony, Jakobsson, Kristina, Li, Ying
Přispěvatelé: Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Occupational and Environmental Medicine, Lund University, Applied Mass Spectrometry in Environmental Medicine, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för arbets- och miljömedicin, Tillämpad masspektrometri inom miljömedicin, Originator, Lund University, Profile areas and other strong research environments, Strategic research areas (SRA), EpiHealth: Epidemiology for Health, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Strategiska forskningsområden (SFO), EpiHealth: Epidemiology for Health, Originator, Lund University, Faculty of Engineering, LTH, Other operations, LTH, Metalund, Lunds universitet, Lunds Tekniska Högskola, Annan verksamhet, LTH, Metalund, Originator, Lund University, Faculty of Medicine, Department of Laboratory Medicine, Division of Occupational and Environmental Medicine, Lund University, Genetic Occupational and Environmental Medicine, Lunds universitet, Medicinska fakulteten, Institutionen för laboratoriemedicin, Avdelningen för arbets- och miljömedicin, Genetisk arbets- och miljömedicin, Originator
Zdroj: Environment International. 204:1-10
Témata: Medical and Health Sciences, Health Sciences, Occupational Health and Environmental Health, Medicin och hälsovetenskap, Hälsovetenskap, Arbetsmedicin och miljömedicin
Popis: BACKGROUND: Some per- and polyfluoroalkyl substances (PFAS) such as perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) are very long-lived in humans, with serum half-lives of several years. In PFAS hot spots, such as Ronneby, Sweden, high exposures over time have led to markedly elevated serum PFAS levels, which may result in health risks as well as transfer to the next generation through pregnancy and breastfeeding. Bile acid sequestrants and organic anion transporter inhibitors are drug candidates for increasing PFAS elimination in humans. MATERIALS AND METHODS: This is a cross-over, clinical study in 10 individuals from Ronneby, Sweden. First, participants were given the bile acid sequestrant cholestyramine and the organic anion transporter inhibitor probenecid for 1 week each. Urinary and fecal concentrations were measured prior, during and after the administration. Then, the changes of serum PFAS concentrations during a 12-week intervention withthe bile acid sequestrant colesevelam were compared to a control period. RESULTS: The study population was mainly exposed to PFHxS (serum mean 50 ng/mL, range 5.8-170), PFOS (serum mean 46 ng/mL, range 9.2-130) and PFOA (serum mean 2.2, range 0.7-4.4). Cholestyramine intervention increased the serum adjusted fecal PFOS concentrations by 23.1 times (95 %CI: 13.6, 39.2), while probenecid was associated with 0.79 times (95 %CI 0.63, 1.0) serum-adjusted urinary PFOS concentrations, compared to no intervention. The 12-week intervention with colesevelam resulted in a mean serum PFOS decline of 38 % (95 %CI -42, -34), compared to 2 % (95 %CI -8, 5) in the control period. The decline was smaller for PFHxS and PFOA. CONCLUSIONS: Bile acid sequestrants could be used for accelerating PFAS excretion in highly PFAS exposed individuals. Studies are needed to evaluate the risks, costs and benefits of using it for this purpose.
Přístupová URL adresa: https://doi.org/10.1016/j.envint.2025.109794
Databáze: SwePub
Popis
Abstrakt:BACKGROUND: Some per- and polyfluoroalkyl substances (PFAS) such as perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) are very long-lived in humans, with serum half-lives of several years. In PFAS hot spots, such as Ronneby, Sweden, high exposures over time have led to markedly elevated serum PFAS levels, which may result in health risks as well as transfer to the next generation through pregnancy and breastfeeding. Bile acid sequestrants and organic anion transporter inhibitors are drug candidates for increasing PFAS elimination in humans. MATERIALS AND METHODS: This is a cross-over, clinical study in 10 individuals from Ronneby, Sweden. First, participants were given the bile acid sequestrant cholestyramine and the organic anion transporter inhibitor probenecid for 1 week each. Urinary and fecal concentrations were measured prior, during and after the administration. Then, the changes of serum PFAS concentrations during a 12-week intervention withthe bile acid sequestrant colesevelam were compared to a control period. RESULTS: The study population was mainly exposed to PFHxS (serum mean 50 ng/mL, range 5.8-170), PFOS (serum mean 46 ng/mL, range 9.2-130) and PFOA (serum mean 2.2, range 0.7-4.4). Cholestyramine intervention increased the serum adjusted fecal PFOS concentrations by 23.1 times (95 %CI: 13.6, 39.2), while probenecid was associated with 0.79 times (95 %CI 0.63, 1.0) serum-adjusted urinary PFOS concentrations, compared to no intervention. The 12-week intervention with colesevelam resulted in a mean serum PFOS decline of 38 % (95 %CI -42, -34), compared to 2 % (95 %CI -8, 5) in the control period. The decline was smaller for PFHxS and PFOA. CONCLUSIONS: Bile acid sequestrants could be used for accelerating PFAS excretion in highly PFAS exposed individuals. Studies are needed to evaluate the risks, costs and benefits of using it for this purpose.
ISSN:18736750
DOI:10.1016/j.envint.2025.109794